-6%

est. 2Y upside i

AI & MLHealthcareSeries A

Rank

#2447

Sector

Precision Medicine, AI & Machine Learning, Biotech

Est. Liquidity

~4Y

Data Quality

Data: Low

Given the stale valuation, high preference stack ($110M on $408M), and missing growth data, the expected equity upside over 2 years is negative (-6.4%).

Last updated: July 19, 2026

Bull (20%)+57%

If Artera capitalizes on recent FDA clearances for breast cancer and expands in prostate, revenue could grow faster; IPO window may sustain lofty multiples near 11x, yielding ~77% pre-dilution upside, net ~57%.

Base (55%)-7%

Revenue grows modestly, multiple converges to ~7x public comps; pre-dilution upside ~13% but 20% dilution turns it negative at -7%.

Bear (25%)-56%

Competition from incumbents or slower adoption compresses multiple to 4x; pre-dilution loss of 35% exacerbated by 20% dilution.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

32070%

Total funding of $110M represents 27% of current valuation, meaning common stock comes after a significant preferred overhang.

Dilution Risk

high

With $110M raised and high capital intensity, a Series B or later round is probable within 2 years, diluting existing common by ~20%.

Secondary Liquidity

none

No secondary market data; shares are likely illiquid until a liquidity event.

Life Sciences — 1 role

View all 8 open roles at Artera →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Artera's data — designed to show you've done your homework.

  • 1

    “How does Artera plan to scale its AI platform across multiple cancer types while maintaining regulatory compliance?”

  • 2

    “What is the unit economics of a per-test license, and how does it compare to existing pathology workflow costs?”

  • 3

    “Given the 2-4 year typical hold for private equity, what liquidity events are realistic for common stock employees?”

Community

Valuation Sentiment

Our model estimates -6% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.